An engineered substance P variant for receptor-mediated delivery of synthetic antibodies into tumor cells.
about
Potent delivery of functional proteins into Mammalian cells in vitro and in vivo using a supercharged proteinSynthetic biology in mammalian cells: next generation research tools and therapeuticsAllosteric control of ligand-binding affinity using engineered conformation-specific effector proteinsTargeted rescue of cancer-associated IDH1 mutant activity using an engineered synthetic antibody.Characterization of engineered actin binding proteins that control filament assembly and structure.Beyond natural antibodies: the power of in vitro display technologies.Green fluorescent protein fused to peptide agonists of two dissimilar G protein-coupled receptors: novel ligands of the bradykinin B2 (rhodopsin family) receptor and parathyroid hormone PTH1 (secretin family) receptor.Generating conformation-specific synthetic antibodies to trap proteins in selected functional statesNew type of BACE1 siRNA delivery to cells.IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.Cellular uptake mechanisms and endosomal trafficking of supercharged proteins.Targeting antibodies to the cytoplasm.Comparative analysis of the methods of drug and protein delivery for the treatment of cancer, genetic diseases and diagnostics.Getting across the cell membrane: an overview for small molecules, peptides, and proteins.Substance P derivatives as versatile tools for specific delivery of various types of biomolecular cargo.Boronate-mediated biologic delivery.Protein engineering strategies with potential applications for altering clinically relevant cellular pathways at the protein level.
P2860
Q24630131-BF70F381-9E41-458F-9C8B-D20989B2E047Q26995293-ED3522AF-0C14-426B-B4CB-A4B5CF0C0FAAQ27667191-8ECFD0CD-1F16-455D-950C-1B24E24CC3DCQ33678027-7E9ECBF0-5FEB-4916-B922-B715D5EB76B6Q33754420-387052AD-7569-493B-ABCB-D01423290881Q33841864-3A05B4FF-79B4-45B1-8698-4D59ADA61146Q34286441-B1A36229-0CFD-456A-82C1-E455D4E3EE57Q34528889-F9BABAD1-9F44-48B6-AAFF-D635C689B04EQ34701500-130E617A-5DEB-4D1B-9620-4D2C28D2BDCCQ35992493-63C46F35-128E-4659-8822-426943218396Q36129709-51380495-E6C5-4923-8ADB-81BCE601201AQ37811739-E9B49108-F083-4344-8189-44C5A9AEB98FQ37921774-A8D23E3D-857F-4C81-A035-B31BF3906973Q38307864-E1A4DB2F-78B0-4171-9BB2-F28A926B0278Q39427146-BA1AAA57-CE62-423A-96CD-CCECF856C45FQ41859282-EE3A7FF2-FB59-4563-AFAF-7F86DA4E654AQ51404723-795B75B6-A8FD-45C9-8008-0ECE12EC3E80
P2860
An engineered substance P variant for receptor-mediated delivery of synthetic antibodies into tumor cells.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
An engineered substance P vari ...... c antibodies into tumor cells.
@ast
An engineered substance P vari ...... c antibodies into tumor cells.
@en
type
label
An engineered substance P vari ...... c antibodies into tumor cells.
@ast
An engineered substance P vari ...... c antibodies into tumor cells.
@en
prefLabel
An engineered substance P vari ...... c antibodies into tumor cells.
@ast
An engineered substance P vari ...... c antibodies into tumor cells.
@en
P2093
P2860
P356
P1476
An engineered substance P vari ...... c antibodies into tumor cells.
@en
P2093
Anna Luchniak
Anthony A Kossiakoff
Crista M Brawley
Ronald S Rock
Serdar Uysal
Shahir S Rizk
P2860
P304
11011-11015
P356
10.1073/PNAS.0904907106
P407
P577
2009-06-22T00:00:00Z